News

• Drug Alert – The FDA Advises Ophthalmologists to Cease Use of Specific Bevacizumab, Lidocaine Lots from Leiter’s Compounding Pharmacy
  

  From the Academy: The Academy is joining the U.S. Food and Drug Administration in alerting members nationwide to check their inventory and cease use of two medications produced by Leiter’s Compounding Pharmacy. Due to concerns of sterility assurance with the pharmacy’s independent testing laboratory, Leiter’s is recalling the following products: Bevacizumab Lot. No. 08052013@1, expiry […]

• Drug Alert – The FDA Advises Ophthalmologists to Cease Use of Bevacizumab and Vancomycin from the Avella Specialty Pharmacy
  

  Alert from the Academy: The Academy is joining the U.S. Food and Drug Administration in alerting members to check their inventory and cease use of two medications produced by Avella Specialty Pharmacy due to concerns of sterility assurance with the pharmacy’s independent testing laboratory. Due to the concerns, Avella is recalling the following products: Bevacizumab […]

• OMIC Declares a 25% Dividend to be Paid in 2014
  

  Benjamin Franklin graces the front of the $100 bill and if you’re an OMIC-insured physician, or if you’re a physician that joins us before year-end, you’ll be seeing a lot more of him next year. As a result of our continued favorable operating performance, we are pleased to announce that OMIC’s Board of Directors approved […]

• HIPAA Business Associate Agreement Now Available
  

  OMIC has completed its revision of the HIPAA Business Associate (BA) Agreement it maintains between itself and each of its insureds. You can download a copy here: Business Associate Agreement-OMIC-9.1.2013. A hard copy is also being sent to you by mail. Please understand that because OMIC has 4,500 physician insureds, it would be administratively burdensome […]